• LIXTE’s lead compound, LB-100, is the world’s first and only clinical-stage inhibitor of protein phosphatase 2A (“PP2A”).
• LB-100 helps in the fight against cancer in a few ways, as it makes cancer cells more sensitive to immunotherapy and chemotherapy, while also disrupting cancer’s internal repair system.
• The compound has demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by over 25 published preclinical and translational studies so far.

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100.

The LB-100 compound is a proprietary small-molecule PP2A inhibitor that is designed to target protein phosphatase 2A (“PP2A”), introducing a potential new treatment paradigm aimed at enhancing existing therapies rather than replacing them.

In short, the compound works around a novel concept known as activation lethality, where it triggers cancer cells to be more vulnerable and susceptible to these therapies and stops their ability to repair themselves once they’ve been damaged. This makes the compound specifically useful against difficult-to-treat cancers, as these will often survive radiation and chemotherapy by repairing DNA damage, a process which LB-100 aims to help prevent.

Without solutions like LB-100, many cancers would remain resistant to common therapies, which inevitably leads to worse outcomes for patients. Also, while some direct natural PP2A inhibitors do exist, these are often too toxic to use safely in treatment.

In addition to being effective and helpful in the fight against cancer, LB-100 has also demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by more than 25 published preclinical and translational studies.

Currently, the compound is being evaluated in numerous leading cancer research institutions, including MD Anderson Cancer Center, the Netherlands Cancer Institute, and international research groups. Ongoing trials for LB-100 include combining it with immunotherapy in metastatic MSI-low colon cancer and ovarian clear cell carcinoma, and combination therapy alongside chemotherapy in advanced soft tissue sarcoma.

These studies are being done in collaboration with leading academic cancer centers and industry partners, highlighting LIXTE’s emphasis on externally validated clinical execution.

For more information, visit the company website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising.

• GPS jamming has emerged as a key modern warfare tactic, using high-powered radio signals to disrupt satellite navigation and shape both offensive operations and defensive countermeasures on the battlefield.
• This sparks major concern for many organizations and military forces, as several aspects of war rely on GPS, such as tracking, navigation, communication, and others.
• To fight back against GPS jamming, companies like SPARC AI have created GPS-free technology to deliver real-time insights, detection, and tracking, without having to rely on radar, lidar, and sensors.

In today’s rapidly evolving battlefield, drones have become one of the most influential tools in modern warfare, reshaping how militaries gather intelligence, navigate contested environments, and execute operations. Yet as drone usage expands, so does the threat of GPS jamming, a tactic that overwhelms satellite signals with high-powered radio interference, effectively blinding autonomous systems and disrupting navigation in critical moments. This challenge is pushing defense technology companies like SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) to develop next-generation solutions that allow drones to operate, navigate, and acquire targets even in GPS-denied environments, where traditional systems would fail.

In war, GPS interference is used to disrupt communications, mislead enemy navigation, ground unauthorized drones, deny precision strikes, and obscure troop or fleet movements. What once seemed like a futuristic electronic warfare tactic is now a daily reality in active conflict zones. Recent interference across the Middle East, particularly in the Strait of Hormuz, has shown how widespread GPS jamming and spoofing can create chaos, with ships appearing on land, navigation systems failing, and maritime traffic slowing dramatically due to unreliable positioning data.

GPS has become a foundational tool for modern military and commercial operations, and when interference occurs, the consequences can be severe. Aircraft and ships can lose situational awareness, vessels may struggle to avoid collisions in crowded shipping lanes, and expensive guided systems risk failure at critical moments.

In addition to jamming, GPS spoofing has also become prevalent and is even more of a problem. Instead of simply interrupting and overwhelming GPS signals like jamming does, spoofing feeds false location data to receivers, causing drones, ships, aircraft, or missiles to believe they are somewhere they are not. In heavily contested regions, this has led to ships broadcasting incorrect positions, navigation systems displaying chaotic movement patterns, and entire fleets slowing or stopping because operators can no longer determine where surrounding vessels are.

As a result, relying solely on GPS is becoming risky, especially in war zones, conflict areas, GPS-denied regions, or places with inconsistent or poor connections. However, companies like SPARC AI Inc. are combating GPS jamming and spoofing by developing GPS-free technology.

Specifically, SPARC AI develops target acquisition systems and autonomous navigation software that uses known landmark coordinates to calculate and correct your position. SPARC AI’s flagship technology, Overwatch, unifies all SPARC AI technologies, including its Target Acquisition, Mobile, and Navigation systems, into a single mission-ready platform that fuses detection, classification, tracking, and navigation in real time. The platform is hardware-agnostic and can integrate across different drone manufacturers and systems, making it scalable for both defense and rescue fleets to conduct surveillance. As more drones use the system, Overwatch strengthens through operational data, improving reliability and mission performance in GPS-denied environments such as active conflict zones.

The platform uses camera telemetry data to figure out the location of any visible object and constructs a 3D understanding of the terrain and position, using advanced mathematical modeling, to get GPS-level accuracy.

With GPS jamming likely remaining a useful tactic going forward in war, adopting a GPS-free approach may help military forces and organizations to navigate, track, and communicate successfully in risky environments.

For more information, visit the company’s website at https://sparcai.co.

NOTE TO INVESTORS: The latest news and updates relating to SPAIF are available in the company’s newsroom at https://ibn.fm/SPAIF

• In the life sciences industry, a robust pipeline is widely recognized as a critical driver of value creation and sustainability.
• The significance of the UK designation extends beyond a single program.
• The UK designation builds on additional regulatory recognition for dusquetide, including orphan drug designation from the FDA for Behçet’s disease.

A strong and diversified pipeline is often the foundation of long-term success in the biotechnology sector, enabling companies to sustain innovation while advancing multiple therapeutic opportunities. Soligenix (NASDAQ: SNGX) is reinforcing that foundation as its investigational therapy SGX945 receives Promising Innovative Medicine designation in the United Kingdom, a development that highlights both the potential of the therapy and the growing strength of the company’s rare disease pipeline.

In the life sciences industry, a robust pipeline is widely recognized as a critical driver of value creation and sustainability. Developing a new medicine is a complex and lengthy process that can take more than a decade and require significant investment, with only a small percentage of drug candidates ultimately receiving approval. Because of these challenges, savvy companies maintain a pipeline of multiple candidates at various stages of development to increase the likelihood of long-term success and to mitigate the inherent risks of drug development.

The importance of a strong pipeline is further underscored by industry data on clinical success rates. Research shows that an estimated 12% of drug candidates that enter clinical trials ultimately receive approval, highlighting the high level of attrition within the development process. This reality reinforces the need for companies to continuously advance new candidates and expand their development programs in order to sustain growth and deliver new therapies to patients.

Beyond risk management, a well-developed pipeline also allows companies to leverage scientific expertise across multiple programs and therapeutic areas. By advancing a portfolio of candidates that may share underlying technologies or mechanisms of action, companies can improve development efficiency and create opportunities for broader clinical impact. This approach is particularly important in the rare disease space, where scientific complexity and limited patient populations make each individual program both challenging and highly significant.

Soligenix’s recent progress with SGX945 reflects this broader strategic focus. According to the company, the UK Medicines and Healthcare Products Regulatory Agency granted Promising Innovative Medicine designation to SGX945 (dusquetide) for the treatment of Behçet’s Disease, a rare inflammatory condition. This designation is awarded to therapies that demonstrate the potential to address serious conditions with unmet medical needs and represents an early step toward inclusion in the United Kingdom’s Early Access to Medicines Scheme.

The significance of this designation extends beyond a single program. By achieving recognition from a major international regulatory authority, Soligenix strengthens the credibility of its development efforts while potentially accelerating the path toward patient access. The Early Access to Medicines Scheme is designed to provide patients with life-threatening or seriously debilitating conditions earlier access to promising therapies prior to full regulatory approval, underscoring the importance of such designations in advancing both clinical development and patient care.

SGX945 is based on dusquetide, a synthetic peptide that belongs to a class of compounds known as innate defense regulators. These molecules are designed to modulate the body’s innate immune response, shifting it toward an anti-inflammatory, anti-infective and tissue-healing profile, representing a novel mechanism of action in immune-related conditions. This approach is being applied to diseases such as Behçet’s disease, a rare inflammatory disorder of the blood vessels characterized by recurring symptoms that can significantly affect quality of life. 

Clinical data referenced in the announcement highlight the therapy’s potential. In a phase 2a pilot study, SGX945 demonstrated improvement in oral ulcer outcomes among patients with Behçet’s Disease, with positive responses observed in seven of eight treated individuals. The therapy was also reported to be well tolerated, with no treatment-related adverse events observed during the study period.

The UK designation builds on additional regulatory recognition for dusquetide, including orphan drug and fast track designations from the U.S. Food and Drug Administration for Behçet’s disease. Such designations can provide important incentives for continued development, including regulatory support and potential market exclusivity, further reinforcing the strategic value of advancing this program within Soligenix’s broader pipeline.

Soligenix continues to develop a diversified portfolio of therapeutic candidates through its specialized biotherapeutics platform. The company’s pipeline includes programs targeting rare inflammatory diseases, oncology indications such as cutaneous T-cell lymphoma and additional areas of unmet medical need. 

The recognition of SGX945 by the UK regulatory authority represents a meaningful step forward not only for the individual therapy but also for the overall strength of Soligenix’s pipeline. In an industry defined by long development timelines and some uncertainty, milestones such as this help validate scientific approaches, support continued investment and bring the possibility of new treatments closer to patients who need them most.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• Cardiovascular disease remains the leading cause of death in the United States, representing a significant and persistent healthcare burden that the company’s solutions are designed to address.
• Cardio Diagnostics has developed a proprietary platform that integrates epigenetic and genetic biomarkers with artificial intelligence to generate personalized cardiovascular insights from a simple blood sample.
• The company’s clinical tests are non-invasive, require no fasting or radiation, and are designed to detect and assess coronary heart disease, including forms that may not be identified through traditional diagnostic methods.
• The company has established multiple commercialization channels, including provider networks, employer partnerships, and community-based programs, to expand access to its cardiovascular testing solutions.
• Recent developments include expanded provider partnerships across the United States, finalized CMS reimbursement rates of $854 for its clinical tests, initial international expansion into India, and clinical data presentations supporting its ability to detect forms of coronary heart disease that traditional tools may miss.

Cardio Diagnostics Holdings (NASDAQ: CDIO) is an artificial intelligence-powered precision cardiovascular medicine company focused on making cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company’s approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators.

At the core of its strategy is the integration of epigenetics, genetics, and artificial intelligence to generate insights from a patient’s molecular profile. By analyzing both inherited predisposition and changes influenced by lifestyle and environment, the company’s platform is designed to provide a more complete view of cardiovascular disease.

Cardio Diagnostics was founded to develop and commercialize clinical tests and data solutions that enable earlier detection and more precise management of cardiovascular disease across clinical and non-clinical settings.

The company is headquartered in Chicago, Illinois.

Portfolio

The company’s portfolio brings together epigenetic and genetic insights with artificial intelligence to generate actionable information for cardiovascular care. This approach underpins a suite of blood-based tests and platforms designed for use across both individual patient care and broader population health settings.

Epi+Gen CHD(TM)

Epi+Gen CHD(TM) is a prescription-only blood test that assesses a patient’s three-year risk of a coronary heart disease (“CHD”) event, including heart attack and sudden death. The test evaluates three epigenetic and five genetic biomarkers and applies artificial intelligence to generate a personalized risk score. It is designed to assess risk regardless of the presence of traditional factors and is non-invasive, requiring no fasting or radiation. In clinical validation studies, the test has demonstrated approximately two times greater sensitivity than conventional risk calculators and enables ongoing monitoring through epigenetic biomarkers that can change in response to intervention.

PrecisionCHD(TM)

PrecisionCHD(TM) is a prescription-only blood test that aids in the detection and management of coronary heart disease by identifying molecular signals associated with the condition. The test evaluates 10 epigenetic and six genetic biomarkers and uses artificial intelligence to determine whether a disease signal is present. It provides patient-specific insights into the molecular drivers of disease, supporting more individualized care decisions, and is designed to detect both obstructive and non-obstructive forms of CHD in a non-invasive manner.

HeartRisk(TM)

HeartRisk(TM) is a population-level cardiovascular risk intelligence platform that integrates anonymized clinical, claims, industry, and geographic data to provide real-time insights into heart disease risk across defined populations. The platform enables organizations to quantify risk, project future healthcare costs, benchmark against peer groups, and track changes over time, supporting more informed planning and risk management strategies.

CardioInnovate360(TM)

CardioInnovate360(TM) is a biopharma research platform that leverages artificial intelligence and epigenetics to support the discovery, development, and validation of cardiovascular therapies. The platform is designed to identify novel biomarkers and disease pathways, optimize clinical trial design through improved patient stratification, and enable the development of scalable, non-invasive diagnostic tools.

Market Opportunity

Cardiovascular disease (“CVD”) is the leading cause of death in the United States, responsible for nearly one in three deaths. It encompasses a range of conditions, including CHD, stroke, heart failure, and peripheral artery disease, and continues to represent a significant and persistent healthcare burden.

Coronary heart disease is the most common form of CVD and often develops without symptoms, with a heart attack frequently serving as the first indication of disease. In the U.S., one in 20 adults over the age of 20 lives with CHD, and it is the second leading cause of hospitalization, adding approximately $13,000 in annual healthcare costs per patient. An additional three to four million Americans are affected by ischemia with no obstructive coronary arteries (“INOCA”), a subset of CHD.

Heart attacks occur approximately every 40 seconds in the U.S., with more than 800,000 events annually, and one in five occurring without warning. While an estimated 80–90% of cardiovascular disease is preventable through early detection and proactive management, traditional approaches can leave gaps, as approximately 50% of individuals with coronary heart disease do not present with traditional risk factors and conventional risk calculators have an average sensitivity of 39%.

Leadership Team

Meesha Dogan, PhD, Chief Executive Officer and Co-Founder, has served as CEO and a director since inception and co-founded the company alongside Dr. Philibert. She has more than a decade of experience working at the intersection of artificial intelligence, epigenetics, and genetics, leading the development and commercialization of DNA-based cardiovascular tests. Dr. Dogan is an inventor on multiple granted and pending patents and holds a PhD in Biomedical Engineering and BSE/MS degrees in Chemical Engineering from the University of Iowa.

Robert Philibert, MD, PhD, Chief Medical Officer and Co-Founder, has served as CMO and a director since inception and co-founded the company with Dr. Dogan. He is a professor at the University of Iowa with joint appointments across psychiatry, neuroscience, molecular medicine, and biomedical engineering, and has published more than 200 peer-reviewed manuscripts. Dr. Philibert has received numerous NIH grants and holds patents related to epigenetics, including work on behavioral biomarkers.

Tim Dogan, PhD, Chief Technology Officer, has served as CTO since May 2022 after joining the company in 2019 as its first employee. He played a key role in developing the company’s Integrated Multi-Omics Engine(TM) and is a co-inventor on multiple patent-pending technologies. Dr. Dogan holds a PhD and BSE/MS degrees in Mechanical Engineering from the University of Iowa.

Elisa Luqman, JD, MBA, Chief Financial Officer, has served as CFO since March 2021 and has experience in public company finance, compliance, and corporate governance. She has held senior leadership roles at Clinigence Holdings Inc. and currently serves as Chief Legal Officer (SEC) at Nutex Health Inc., overseeing SEC reporting and compliance. Ms. Luqman holds a JD and MBA in Finance from Hofstra University.

For company information, visit the company’s website at https://cdio.ai.

NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

• ESGold Corp., a development-stage company committed to the acquisition, exploration, and development of high-quality mineral properties worldwide, continues to demonstrate why gold is a viable investment in 2026.
• Despite the high volatility of gold and silver over the past year, the ongoing rise of worldwide debt, and its effect on currency and inflation, is expected to continue as a fundamental driver for such tangible assets.
• The active mining of gold represents both a productive business operation and a high-value end product, a buffer to volatility and an easy market-friendly way for investors to take advantage of periodic dips in precious metal markets.

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF), a development-stage company committed to acquiring, exploring, and developing high-quality mineral properties worldwide, continues to demonstrate why and how gold is a viable investment in 2026, particularly compared to investment alternatives. As a company heavily invested in the industry, ESGold is making it easier for people to get into gold by investing in the companies that produce it, a still under-appreciated opportunity for most investors. Construction at their Montauban project in Quebec, the company’s major focus, is rapidly advancing toward gold-silver concentrate production with a 2026 timeline.

Price volatility in precious metals is expected to continue with geopolitical shifts. After its major surge in 2025, gold hit an all-time high in January 2026, then dropped about 15% by early February, only to rise back up to near record highs by the end of that month, then dropping 17% in March. However, the drivers of long-term appreciation are only increasing. Worldwide economic debt and inflation fears are becoming foundational, and have a long history. For context, over the past 30 years, the price of gold has grown from $327 to over $4,000 an ounce. 

As a demonstration of ESGold’s bullish outlook on gold’s price and its value as an investment vehicle, the company has been transitioning from developer to producer, and has closed a C$7.2 million offering to expand exploration on its flagship Montauban property.

“This next phase marks an important step in defining the full scale of Montauban,” noted ESGold’s CEO, Gordon Robb. “Our initial ANT survey and integrated 3D model revealed a deep and expanding mineralized corridor extending to approximately 900 meters and over at least two kilometers of strike. The expanded 70 square kilometer program is seven times larger than our initial survey and represents the most comprehensive geophysical assessment ever conducted across the Montauban district,” he added (https://ibn.fm/eFubr).

For company information, visit the company’s website at www.ESGold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

Disseminated on behalf of  Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.

• The conflict involving Iran, with associated tensions between Washington and Beijing, are increasing scrutiny of critical mineral supply chains, particularly rare earth elements (“REEs”).
• China controls roughly 90% of the world’s processed rare earth supply, giving Beijing significant leverage over global technology and defense manufacturing.
• Beijing has expanded export controls on several rare earth elements and related technologies, reinforcing its dominance in the supply chain.
• Western governments are accelerating efforts to build alternative supply sources in North America, with funding and procurement programs emerging in both the U.S. and Canada.
• Exploration companies such as Powermax Minerals are advancing REE projects in Canada and the United States, all of which are in a position to benefit from growing geopolitical pressures.
• Powermax’s projects in British Columbia, Ontario, and Wyoming, place it in jurisdictions aligned with U.S. and Canadian critical-minerals policy.

The war involving Iran has added a new layer of complexity to global supply chains already strained by geopolitical rivalry between the United States and China. Energy markets have reacted first. With the Strait of Hormuz partially disrupted, oil flows have tightened and prices have risen. Yet analysts note that China has been able to buffer the shock through large strategic stockpiles and “shadow” shipments from Iran, allowing Beijing more flexibility in how it manages the crisis (https://ibn.fm/0dbUQ).

The broader strategic concern for Washington and its allies lies beyond oil. Rare earth elements (17 metals essential to modern electronics, electric vehicles, advanced weapons systems and renewable energy technologies) remain heavily concentrated in China’s supply chain. 

China accounts for over 90% of global rare-earth processing capacity, according to reporting by Reuters (https://ibn.fm/LypEG). Recent export controls expanded restrictions to several additional elements and technologies, highlighting how Beijing could use the sector as leverage in geopolitical disputes. For Western governments seeking to reduce that dependence, the search for alternative supplies has become a strategic priority.

The push to diversify rare earth supply is gaining momentum. Policymakers in the United States and Canada have begun directing public funding toward domestic mining and processing capacity, including grants and long-term procurement commitments tied to national security. The urgency of that effort has grown as tensions rise between Washington and Beijing over trade, technology and geopolitical alignment. If China further restricts rare earth exports, particularly in response to global conflicts or sanctions, the ripple effects could hit sectors ranging from semiconductor manufacturing to aerospace.

This dynamic encourages renewed investor interest in early-stage exploration companies developing deposits outside China’s sphere of influence.

Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF) is a Canadian mineral exploration company focused on rare earth projects across North America. The company is building a portfolio that includes the Cameron REE project in British Columbia, the Atikokan and Pinard properties in Ontario, and the Ogden Bear Lodge project in Wyoming. While still in the exploration stage, these projects sit within mining-friendly jurisdictions with infrastructure access and growing policy support for critical minerals development. 

Powermax has already reported encouraging exploration data from its Canadian properties. At the Cameron project in British Columbia, soil and rock sampling programs have identified elevated concentrations of rare earth elements within a mineralized corridor more than a kilometer long. Sampling returned Total Rare Earth Oxide (“TREO”) values ranging from roughly 135 parts per million to 2,840 ppm, suggesting the potential presence of REE-bearing pegmatites beneath shallow overburden.

The property spans approximately 2,984 hectares in the Kamloops Mining Division, an area known for granitic and metamorphic formations capable of hosting rare earth mineralization.

Meanwhile, the company’s Atikokan property in northwestern Ontario has been the focus of geochemical and geophysical surveys aimed at identifying priority exploration targets.

The significance of projects like those being explored by Powermax lies partly in timing. As relations between the United States and China grow more uncertain, governments are increasingly concerned about supply vulnerabilities in materials used for defense systems, electric vehicles, and renewable energy infrastructure.

China has already demonstrated its willingness to restrict exports of critical minerals in response to geopolitical tensions. The latest licensing requirements and export controls on rare earth elements reinforce Beijing’s ability to shape global supply chains.

In a prolonged geopolitical confrontation, whether driven by trade disputes, technology competition or regional conflicts such as the Iran crisis, Western nations may accelerate the development of domestic rare earth resources. That shift could increase the strategic importance of exploration companies operating within allied jurisdictions.

Rare earth mining projects typically require years of exploration, environmental review and development before reaching production. That timeline means early-stage companies like Powermax represent long-term bets on both geological success and geopolitical trends.

If that effort succeeds, the next generation of rare earth deposits developed in North America could play a role in reshaping a critical corner of the global minerals market. For companies already exploring those resources, the evolving geopolitical landscape may increase both attention and potential value in the years ahead.

For more information, visit the company’s website at www.PowermaxMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to PWMXF are available in the company’s newsroom at https://ibn.fm/PWMXF

Exploration Target Cautionary Statement

The exploration targets discussed are conceptual, and there is currently not enough data to confirm a mineral resource. Further exploration may not yield successful results.

• 2026 has been a volatile period in the crypto market, but the current state of the industry serves as a unique and unexpected opportunity to invest in something that was much more expensive only a short time ago.
• While periodic ups and downs are to be expected, due to outside factors, all of the long-term forces supporting the move to blockchain and digital currencies remain in play.
• This applies to Solana (SOL), thanks to its high speed, low transaction cost, and high transaction volume, and to Forward Industries Inc., the largest SOL treasury and an easy way to enter the market by simple share purchase.

The crypto market has gone through plenty of volatility in 2026 so far, and this is continuing due to ongoing geopolitical factors around the world. But with cryptocurrencies being down so far this year, investors are faced with an opportunity to get into a market that was much more expensive only a few short months ago. The long-term forces supporting the move to blockchain-based currencies in the future are still there, and show no signs of going away. 

The crypto market has, for example, seen more institutional adoption, as many banks and financial institutions are tokenizing real-world assets and/or integrating digital assets into portfolios. The world continues to establish clearer regulations and legal frameworks surrounding cryptocurrencies, important for institutional confidence and reduced risk as well as the financial inclusion of unbanked or underbanked people around the world seeking access to financial services and digital wallets. It’s a market based on a technology that offers low transaction costs, high speeds, better accessibility, and 24/7 operation.

Solana (SOL) is seen as one of the most performant cryptocurrencies, due to high transaction volumes, fast speeds, and very low transaction costs. In turn, this idea also applies to Forward Industries (NASDAQ: FWDI), which is a large-scale Solana treasury company and the biggest publicly-traded Solana treasury platform, with over 6.9 million SOL in total holdings. It also has a validator infrastructure that has generated between 6.5% and 7.2% gross annual percentage yield before fees, which outperforms many peer validators. Forward Industries also actively participates in the Solana ecosystem, by using assets for on-chain activities like staking, lending, and participating in decentralized finance (“DeFi”).

Most importantly, Forward Industries represents an easy way for investors to take advantage of current market prices and ride the long-term crypto wave, by simply buying shares of the company.

About Forward Industries Inc. (NASDAQ: FWDI)

Forward Industries is a company that’s building and managing a large-scale Solana treasury, and is backed by many of the most influential investors in the digital space. The company’s strategy focuses on creating long-term shareholder value by actively participating in the Solana ecosystem. It does this by strategically deploying assets through on-chain opportunities like staking, lending, and participating in decentralized finance (“DeFi”).

For more information, visit the company’s website at www.ForwardIndustries.com.

NOTE TO INVESTORS: The latest news and updates relating to FWDI are available in the company’s newsroom at https://ibn.fm/FWDI

• Researchers are increasingly focused on combination therapies and novel mechanisms of action that can enhance tumor response to treatment.
• LIXTE’s LB-100 is designed to sensitize cancer cells to chemotherapy and potentially enhance immune system activity, offering a complementary approach to existing treatments.
• The company recently announced the expansion of its ongoing clinical trial in clear cell ovarian cancer, including an increase in patient enrollment that effectively doubles the size of the study.

Ovarian clear cell carcinoma and metastatic colon cancer remain among the most challenging malignancies to treat, with limited effective therapies and poor patient outcomes driving the urgent need for new approaches. LIXTE Biotechnology Holdings (NASDAQ: LIXT) is dedicated to addressing that need through the continued development of its lead compound LB-100. Recent updates from the company highlight expanding clinical trial activity designed to evaluate the drug’s potential across these difficult-to-treat cancers.

Ovarian cancer remains a serious global health concern, and the clear cell subtype presents additional treatment challenges. According to the American Cancer Society (ACS), more than 21,000 women in the United States are expected to be diagnosed with ovarian cancer this year, with an estimated 12,500 deaths projected. Clear cell ovarian cancer, while less common than other subtypes, is often associated with resistance to conventional chemotherapy, making it particularly difficult to treat effectively.

Metastatic colorectal cancer presents a similarly urgent challenge. The ACS reports that colorectal cancer is one of the most diagnosed cancers in the United States, with an estimated 158,850 new cases and 55,230 deaths expected in 2026. When the disease progresses to a metastatic stage, treatment options become more limited and survival rates decline significantly, underscoring the importance of developing therapies that can improve outcomes in advanced disease.

Researchers are increasingly focused on combination therapies and novel mechanisms of action that can enhance tumor response to treatment. LIXTE’s LB-100 is a small-molecule inhibitor targeting protein phosphatase 2A (PP2A), an enzyme involved in regulating cell growth, DNA damage repair and immune signaling pathways. By inhibiting PP2A, LB-100 is designed to sensitize cancer cells to chemotherapy and potentially enhance immune system activity, offering a complementary approach to existing treatments.

LIXTE recently announced the expansion of its ongoing clinical trial in clear cell ovarian cancer, including an increase in patient enrollment that effectively doubles the size of the study. The trial is being conducted in collaboration with leading research institutions, including the University of Texas MD Anderson Cancer Center, which is widely recognized for its work in cancer research and clinical care. Expanding enrollment is a meaningful step in clinical development, as it allows researchers to gather more robust data on safety, tolerability and potential efficacy across a broader patient population.

The study is focused on evaluating LB-100 in combination with chemotherapy for patients with ovarian clear cell carcinoma, a disease that often shows resistance to standard treatments. By combining LB-100 with existing therapies, researchers are looking to determine whether the drug can improve response rates and overcome some of the resistance mechanisms that limit current treatment options.

In addition, LIXTE is working with pharmaceutical manufacturer GSK in its clinical development efforts, reflecting a broader trend in the pharmaceutical industry toward partnerships between smaller biotechnology companies and large pharmaceutical entities. Such collaborations can provide additional resources, expertise and infrastructure to support clinical trials and accelerate development timelines.

“We are gratified to be expanding the patient population of this important clinical trial,” said LIXTE chief scientific officer Bas van der Baan. “There is a tremendous unmet need in the treatment of ovarian clear cell cancer. Based on extensive published preclinical data, we believe LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve patient outcomes.”

Beyond ovarian cancer, LIXTE is also advancing research involving metastatic colon cancer. Clinical studies are exploring the potential of LB-100 in combination with other therapies to improve treatment outcomes in patients with advanced colorectal cancer. This reflects the company’s broader strategy of evaluating its PP2A inhibition approach across multiple tumor types where resistance to therapy remains a significant challenge.

According to LIXTE, the mechanism of action behind LB-100 may increase tumor immunogenicity by enhancing neoantigen production and promoting T-cell proliferation, which could help make tumors more responsive to both chemotherapy and immunotherapy. This aligns with a growing body of research suggesting that modifying the tumor microenvironment and improving immune recognition may be key to improving outcomes in difficult cancers.

The expansion of clinical trials is an important milestone for any biotechnology company, as it signals progress in moving a drug candidate through the development pipeline. Increasing patient enrollment, broadening study populations and strengthening collaborations with leading institutions all contribute to building a more comprehensive data set that can support future regulatory and commercialization efforts.

LIXTE’s continued advancement of LB-100 reflects its focus on addressing unmet medical needs in oncology. By targeting fundamental biological pathways involved in cancer growth and immune response, the company aims to develop therapies that can enhance the effectiveness of existing treatments while offering new hope for patients with limited options.

For more information, visit the company website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) and may include paid advertising.

• Canadian near-term gold producer LaFleur Minerals recently released the results of a Preliminary Economic Assessment (“PEA”) outlining a capital efficient project with robust economic returns
• LaFleur executives Kal Malhi (Chairman) and Paul Ténière (CEO and Director) participated in a March 24 webinar where they discussed the positive PEA results with investors as well as outlining some of the company’s next steps
• LaFleur’s strategy is based on a low CapEx mine-to-mill project, which includes a wholly owned and permitted gold mill approaching restart readiness, a tailings pond and a gold deposit that has undergone advanced exploration outlining expansion and scalability
• The mill is expected to begin processing material in the spring, thanks partly to the success of prior capital raises, with another anticipated in April or May

LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) executives promoted the company’s expectations for a straightforward path to profitability, backed by the results of a recently completed Preliminary Economic Assessment (“PEA”), during a March 24 webinar with investors. 

Board of Directors Chairman Kal Malhi pointed out the advantages of LaFleur’s three-tiered economic model, which includes the interconnected relationship between the company’s Beacon Gold Mill, the tailings pond at the mill, and the Swanson Gold Deposit all located within close proximity to each other in the prolific Tier‑1 Abitibi Greenstone Belt of Eastern Canada. 

“That PEA shows healthy economics,” Malhi said before inviting questions from webinar participants. “We’re a junior gold company but we’re very unique in having those three assets. … Our Beacon Mill is 20 minutes out of the town Val d’Or, which is the best mining town in Canada. And the Swanson Project isn’t too far, so our staff could live in Val d’Or, go to work every day. This isn’t a project where we’re flying in material and staff and building camps. So with the price of gold where it is, having the mill ready to go, that’s a unique investment opportunity, I think.”

CEO and Director Paul Ténière noted that the PEA’s very conservative base case metric is established on a market in which gold would be trading at $2,750 per ounce, with All-In Sustaining Costs (“AISC”) that allow for profitability with an after-tax IRR of 65% and a rapid payback period of 1.8 years. Given that gold has been trading mostly between $4,500 and $5,500 per ounce during the past three months, Ténière said recent market fluctuations have not been a concern. “With this being such a low-cost operation, we don’t anticipate any issues there at all,” he said.

LaFleur is aiming to restart the Beacon Gold Mill this spring, to capitalize on the robust price of gold. The mill was formerly owned by Monarch Mining, who refurbished the mill for about $20 million in 2022, Malhi said. LaFleur obtained the mill and the Swanson deposit at a bankruptcy sale two years ago and is nearing the finish line on its efforts to resume operations at the site, which would be a major pivot point for the company as it enters revenue generation.

“The Beacon Gold Mill is fully permitted, refurbished, and funded for restart following a C$7 million financing,” recent analysis by Zacks Small Cap Research states (https://ibn.fm/Z02EY). “With multiple catalysts ahead, including ongoing drill results, bulk sample approval, and mill commissioning, the company is positioned for a meaningful re-rating as it advances toward production.”

Malhi said the company plans a new capital raise in April or May. The executives noted that the mill’s current processing capacity is around 750 metric tons of material per day, but after LaFleur meets its initial target of restarting the mill with a gold pour from a Swanson bulk sample, the company aims to upgrade the mill to 3,000 to 4,000 tonnes per day, which would put it in the category of about 100,000 ounces per year. 

The mill “is able to process gold, silver, and even a little bit of base metals as well, so it can handle multi-element-type deposits,” Ténière said during a separate event last month (https://ibn.fm/xNRbi).

The initial Swanson Deposit obtained from Monarch was “fairly small” — 6,000 hectares (14,826 acres), Malhi said. But LaFleur continued to increase its exploration potential, obtaining additional area from Abcourt Mines and Globex Mining to position its project size at about 19,214 hectares (47,479 acres) currently. “We did that by incorporating other known deposits within the area, and especially to the south,” Ténière said. “Our goal is to continue to increase the size of the resource. Not just at the Swanson Deposit but across the entire project area.”

There are two major structures running through the project and Ténière said, “We have over 50 showings in some cases including for gold, for base metals.”

A recording of the webinar will be placed on the company’s website.

For more information, visit the company’s website at LaFleurMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to LFLRF are available in the company’s newsroom at https://ibn.fm/LFLRF

Qualified Person Statement:

All scientific and technical information contained in this article has been reviewed and approved by Louis Martin, P.Geo. (OGQ), Exploration Manager and Technical Advisor of the company and considered a Qualified Person for the purposes of NI 43-101.

Disseminated on behalf of Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) and may include paid advertising.

• Arctic deposit grades are approximately 5.6% copper equivalent, with a projected mine life of 13 years at planned throughput, placing it among the highest-grade undeveloped copper projects globally.
• The Trump administration has reinstated the 2020 record of decision for the Ambler Access Road in Alaska through a presidential decree, while the repeal of Public Land Order 5150 could remove approximately 25 miles of road from federal permitting jurisdiction entirely.
• The U.S. Department of War committed $35.6 million to the Upper Kobuk Mineral Projects and a 10% stake in Trilogy Metals, signaling direct federal backing for the advancement of one of Alaska’s most strategically important critical mineral districts.

The critical minerals conversation has been building for years, but the policy environment has only recently begun to catch up with geology. As governments increasingly look to provide capital commitments, and as acquisition activity continues to shrink the pool of viable domestic copper developers, the projects that combine strong resource quality with the improving regulatory environment are drawing a new caliber of investor attention. Alaska’s Ambler Mining District stands out as one of those rare convergence points, and the company holding the keys to a distinct land package within it has just delivered one of the more consequential quarters in its history.

A Deposit That Stands Apart

At the center of Trilogy Metals’ (NYSE American: TMQ) (TSX: TMQ) portfolio is their flagship asset Arctic deposit, a volcanogenic massive sulfide (VMS) system containing copper, zinc, silver, gold, and lead in northwest Alaska. What distinguishes Arctic from most other undeveloped projects in the space is not just the multi-metal composition, but the grade. On a copper equivalent basis, the deposit grades approximately 5.6%, a figure that CEO Tony Giardini noted in a recent Kitco interview stands apart from virtually any comparable project in development today.

The deposit contains approximately 50 million tonnes of copper, supporting a projected mine life of 13 years at a planned throughput of 10,000 tonnes per day. At a base case copper price of $3.65 per pound, the pre-tax net present value of Arctic is estimated around $1.5 billion, with a capital intensity ratio of approximately $10,000 per copper equivalent tonne, placing it in the lowest quartile among global copper development projects on that measure.

The investment thesis, however, extends well beyond a single asset.

A District, Not Just a Deposit

The Ambler Mining District was discovered in the 1950s, yet only approximately 210,000 meters of drilling has been completed across its entire strike length in the seven decades since. By comparison, the world’s great VMS districts have typically seen upward of three million meters drilled. The Ambler Mining District, by that measure, has barely been tested.

Alongside Arctic, the Bornite deposit adds further scale with copper and cobalt mineralization. The district also shows indications of germanium, an element with significant defense applications.

Together, Arctic and Bornite position the Ambler Mining District as a potential multi-decade critical mineral development platform.

The Road Question, Materially Answered

For years, development at the Ambler Mining District has been constrained by infrastructure, specifically the proposed 211-mile Ambler Access Road that would connect the district to the existing state road network. A series of permitting approvals, reversals, and litigation created years of uncertainty that dampened progress.

That picture has shifted meaningfully. The Trump administration reinstated the 2020 record of decision through a presidential decree, and the Department of Interior’s repeal of Public Land Order 5150 could remove approximately 25 miles of the road from federal permitting jurisdiction, transferring it to state oversight. The only major federal permit now required for the road is the Section 404 wetlands permit. As Giardini described in the Kitco interview, the project is in a stronger permitting position today than even when the original 2020 approval was first issued.

Federal Capital as Strategic Endorsement

In October 2025, the U.S. Department of War committed $35.6 million for a 10% stake in Trilogy, structured as a direct 5% equity subscription and a 5% acquisition of an existing South32 shareholder position. 

The DOD investment opens doors to broader project financing discussions, and the agreement allows the government to appoint an independent director to the board, providing additional visibility and institutional alignment as the project advances.

Trilogy also maintains its joint venture with South32 through Ambler Metals LLC, a partnership that has seen South32 commit approximately $200 million to the assets since the JV was formed. Together, the private-sector partnership and federal investment place the project among the few North American assets receiving attention from both sides.

Execution Ahead

Looking into 2026 and beyond, Trilogy’s near-term agenda is defined by execution. The company expects to initiate the mine permitting process within months, targeting the FAST-41 framework, which carries an expected timeline of 18 to 24 months. A drilling program is expected to run from May through September as technical work will be conducted to support a final future investment decision for mine construction and operations.

The financing picture is also evolving in the company’s favor. Precious metals now represent approximately 25% of Arctic’s deposit value, up from roughly 10% at the time of the 2023 feasibility study. That shift could open the door to silver and gold streaming arrangements as the project de-risks toward a potential final investment decision targeted in early 2028.

With domestic copper scarcity increasing as consolidation continues across the sector, the Ambler Mining District’s combination of grade, scale, improving infrastructure certainty, and federal alignment places it within a shrinking pool of projects capable of delivering what the supply chain increasingly demands.

For more information, visit www.trilogymetals.com.

NOTE TO INVESTORS: The latest news and updates relating to Trilogy Metals are available in the company’s newsroom at ibn.fm/TMQ